The autism biomarkers consortium for clinical trials: evaluation of a battery of candidate eye-tracking biomarkers for use in autism clinical trials

ConclusionsAll ET tasks met expectations regarding biomarker properties, with strongest performance for tasks associated with attention to human faces and weakest performance associated with biological motion preference. Based on these data, the OMI has been accepted to the FDA ’s Biomarker Qualification program, providing a path for advancing efforts to develop biomarkers for use in clinical trials.
Source: Molecular Autism - Category: Molecular Biology Source Type: research